Patrick Burnett, See Remarks at Arcutis Biotherapeutics, Inc. (ARQT), sold 122,806 shares at $14.97 ($1.8M) on 2025-03-13, disclosed to the SEC on 2025-03-17.
Scheduled sale ($1.8M) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.97 | 44,153 | $661K | 35.9% |
| 2 | $14.97 | 44,153 | $661K | 35.9% |
| 3 | $15.10 | 5,008 | $76K | 4.1% |
| 4 | $15.10 | 5,008 | $76K | 4.1% |
| 5 | $15.04 | 12,242 | $184K | 10.0% |
| 6 | $15.04 | 12,242 |
| $184K |
| 10.0% |
| Total | $14.99 avg | 122,806 | $1.8M | 100% |
| Filing → |
| ARQT | SELL | 2026-08-05 | $25K | — | Filing → |
| ARQT | SELL | 2026-05-13 | $5K | — | Filing → |
| ARQT | SELL | 2026-05-06 | $16K | — | Filing → |